Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanabenz in Early-Childhood Onset Vanishing White Matter
2023-503320-89-00Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of guanabenz in leukoencephalopathy with vanishing white matter (VWM), sponsored by Amsterdam University Medical Center. Primary endpoint: Safety and tolerability (adverse events and serious adverse events). Started Sep 2024; status: completed.
02
Drugs
guanabenz
03
Conditions
leukoencephalopathy with vanishing white matter (VWM)
Beyond the preview
Go deeper on 2023-503320-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503320-89-00.